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background: Long-term clinical benefit of intensive lipid therapy was investigated in a 20-year follow-up of the Familiar Atherosclerosis Treatment 
Study - Observational Study (FATS-OS).
methods: One hundred seventy-five CAD subjects with ApoB≥125mg/dl, mean LDL-C of 191 mg/dl, and mean age of 50 years, who completed 
the randomized and placebo controlled FATS by 1989, were given a choice of receiving lipid management by their primary care physicians as usual 
care (UC) group or an intensive lipid therapy designed for FATS-OS as intensive treatment (IT) group. Of 175, 100 choose UC and 75 elected to 
receive triple therapy IT of lovastatin (40mg/day), niacin (2.5g/day) and colestipol (20g/day) from 1990 to 2004, followed by double therapy with 
simvastatin (40-80mg/day) and niacin, either slow-release (2g/day) or immediate-release (4g/day), from 2005 to 2006 due to discontinuation of 
colestipol. During 2007-2012, triple therapy of vytorin (10/10-80 mg/day) plus niacin (same type and dosage in 2006) was used. UC represented 
an increased intensity of LDL-C lowering influenced by the guidelines over time. Death from cardiovascular (CV), non-cardiovascular (non-CV) and any 
cause was compared between UC and IT using Cox proportional hazards model.
results: UC and IT were similar in clinical risk factors, except IT had severer CAD, at entry of FATS-OS. Follow-up in person-years (PY) was 1,876 
and 1,699 for the UC and IT groups. Mean LDL-C levels were at 166 mg/dl from 1990 to 1998, 103 from 1999 to 2004, 100 from 2005 to 2006, 
and 85 from 2007 to 2012 in surviving subjects receiving UC at each time period. IT lowered LDL-C to 102 mg/dl from 1990 to 1998, 90 from 
1999 to 2004, 96 from 2005 to 2006, and 71 from 2007 to 2012. Compared to UC, IT significantly reduced CV mortality (4.1 vs. 13.9 per 1,000 PY, 
HR=0.29, 95% CI: 0.12-0.66, p=0.002), non-CV mortality (6.5 vs. 13.9 per 1,000 PY, HR=0.44, 95% CI: 0.22-0.89, p=0.02), and total mortality over 
20 years (10.6 vs. 27.7 per 1,000 PY, HR=0.37, 95% CI: 0.21-0.62, p<0.001),
conclusions: A long-term intensive lipid therapy significantly reduced cardiovascular, non-cardiovascular and total mortality in FATS-OS. These 
results indicate the importance of life-time risk reduction.
